Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simurosertib in advanced solid tumors
NCT02699749Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Mar 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of simurosertib in solid tumor, sponsored by Millennium Pharmaceuticals. Primary endpoints: Dose Limiting Toxicities at Cycle 1 and Treatment-emergent Adverse Events. Started Mar 2016; status: completed.
02
Drugs
simurosertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02699749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02699749.